CorMedix Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $311.7M | $43.5M | — | $65,408 | $190,936 |
| Gross profit | $275.7M | $40.3M | — | $61,674 | $41,998 |
| Operating income | $150.1M | -$22.4M | -$49.0M | -$30.6M | -$29.4M |
| Operating expenses | $125.6M | $62.6M | $49.0M | $30.7M | $29.5M |
| Cost of revenue | $22.1M | $3.0M | — | $3,734 | $148,938 |
| Cash from operations | $175.0M | -$50.6M | -$38.4M | -$24.4M | -$21.2M |
| Capital expenditure | $2.3M | $116,000 | $327,300 | $219,360 | $1.4M |
| Free cash flow | $172.8M | -$50.7M | -$38.7M | -$24.6M | -$22.6M |
| Total assets | $826.1M | $118.8M | $82.1M | $62.0M | $68.9M |
| Total liabilities | $420.8M | $34.2M | $11.9M | $7.0M | $6.1M |
Shares outstanding 78.5M · Free float 84.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.